Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

In This Issue

In This Issue • Prognostic Impact of KRAS KRAS transition versus transversion mutations (p = Mutation Subtypes in 677 0.99), smoking status (p = 0.33), or specific amino acid Patients with Metastatic substitutions (p = 0.20). Shorter overall survival was Lung Adenocarcinomas observed in patients with KRAS G13 mutation versus those with KRAS G12 mutations in univariate analysis (1.1 versus 1.3 years; p = 0.009) and multivariate analysis (hazard ratio = 1.52; p = 0.008). However, no survival difference between patients with KRAS G13 and G12 mutations was found in an external multi- institution validation cohort with stage IV KRAS-mutant lung cancers (n = 682; 1.0 versus 1.1 years; p = 0.41). To conclude, KRAS mutation subtypes do not seem to The authors sought to determine the association between KRAS have any prognostic impact in this series of patients. mutation subtypes and overall survival in 677 patients with KRAS- Forthcoming investigation into concurrent mutations mutant metastatic or recurrent lung cancers during a 6-year period. and variable gene expression could identify potential In this cohort of patients with KRAS mutation at G13 (n = 53) prognostic markers for patients with lung cancer with and G12 (n = 624), no overall survival difference was http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

In This Issue

Journal of Thoracic Oncology , Volume 10 (3) – Mar 1, 2015
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/in-this-issue-1OdSyK0Vlf

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000494
pmid
25695216
Publisher site
See Article on Publisher Site

Abstract

• Prognostic Impact of KRAS KRAS transition versus transversion mutations (p = Mutation Subtypes in 677 0.99), smoking status (p = 0.33), or specific amino acid Patients with Metastatic substitutions (p = 0.20). Shorter overall survival was Lung Adenocarcinomas observed in patients with KRAS G13 mutation versus those with KRAS G12 mutations in univariate analysis (1.1 versus 1.3 years; p = 0.009) and multivariate analysis (hazard ratio = 1.52; p = 0.008). However, no survival difference between patients with KRAS G13 and G12 mutations was found in an external multi- institution validation cohort with stage IV KRAS-mutant lung cancers (n = 682; 1.0 versus 1.1 years; p = 0.41). To conclude, KRAS mutation subtypes do not seem to The authors sought to determine the association between KRAS have any prognostic impact in this series of patients. mutation subtypes and overall survival in 677 patients with KRAS- Forthcoming investigation into concurrent mutations mutant metastatic or recurrent lung cancers during a 6-year period. and variable gene expression could identify potential In this cohort of patients with KRAS mutation at G13 (n = 53) prognostic markers for patients with lung cancer with and G12 (n = 624), no overall survival difference was

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Mar 1, 2015

There are no references for this article.